TOLERABILITY AND PHARMACODYNAMIC EFFECT OF REGN9933, A MONOCLONAL ANTIBODY DIRECTED AGAINST THE FACTOR XI APPLE 2 DOMAIN: RESULTS FROM A FIRST-IN- HUMAN STUDY

The requested reference [82d93970c79e4fcce78c938a49d6e19b32cc3cca] no longer exists in our database. It has been replaced by the current reference: [56d9ddcde95f8f3c6ab98f999aec162202111372]

Authors
Category Primary study
ConferenceAbstract Proceedings of the Thrombosis & Hemostasis Summit of North America
Year 2025
This article has no abstract
Epistemonikos ID: 29145a6013a10da74f5111c53a8811b549e943b5
First added on: Jan 31, 2026